Why did ENTX's trading volume surge?

The trading volume of ENTX has surged due to a combination of factors: 1. **FDA Approval Update**: The FDA's agreement on BMD as the primary endpoint for the EB613 study was a significant milestone. This endorsement shifted the paradigm for placebo-controlled phase 3 studies of new osteoporosis drugs, where change in total hip BMD is evaluated as the primary endpoint. This development likely bolstered investor confidence in the company's prospects. 2. **Stock Price Movement**: ENTX's stock price experienced a notable increase of 10.75% on July 25. Such price movements can attract additional attention from investors, potentially leading to increased trading activity. 3. **Market Dynamics**: The overall market environment, including factors like economic data, interest rates, and tariff uncertainties, can influence trading volumes. For instance, the market's caution regarding tariff negotiations and the Fed's stance on interest rates could lead to increased trading activity in certain sectors, including bio-pharmaceuticals. In conclusion, ENTX's trading volume surge is a result of a combination of factors including FDA approval, stock price movement and market dynamics. |code|Ticker|Name|Date|Percentage Change|market_code| |---|---|---|---|---|---| |ENTX|ENTX.O|Entera Bio|20250728|10.7527|186| |ENTX|ENTX.O|Entera Bio|20250729|-1.9417|186| |ENTX|ENTX.O|Entera Bio|20250730|0|186| |ENTX|ENTX.O|Entera Bio|20250731|-4.4554|186| |ENTX|ENTX.O|Entera Bio|20250801|1.0363|186| |ENTX|ENTX.O|Entera Bio|20250802|1.0362694300518145|186|